• br Hepatitis C virus HCV infection is a major

  2022-08-04

  

  Hepatitis C virus (HCV) infection is a major cause of chronic liver disease that can lead to cirrhosis and hepatocellular carcinoma. It is estimated that nearly 200 million individuals worldwide are currently infected with HCV and it is the leading cause of liver transplants. The current standard

• Camptothecin is a type of topo

  2022-08-04

  

  Camptothecin is a type of topo I inhibitor, and its prodrugs irinotecan and topotecan have been approved by the FDA for clinical cancer treatment. It has been reported that SAHA can enhance the cytotoxicity of camptothecin derivatives in several cancer cell lines20., 21., 22., 23., 24.. Taking the s

• Lastly haspin inhibitor was assessed against a panel

  2022-08-04

  

  Lastly, haspin inhibitor was assessed against a panel of 292 kinases at 10μM. At this high concentration, the Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) inhibited thirteen kinases, in addition to haspin, ⩾90%., These kinases were CaMK2b, CaMK2d, CDK7-CycH-Mat1, cGK2, CK1d, CLK1, CLK2, DYR

• The present results indicate that oxidative damage in

  2022-08-04

  

  The present results indicate that oxidative damage in CFS muscles is not due to the decline in the efficiency of antioxidative enzymes. This suggests that there is an increase in the generation of reactive oxygen species consistent with a mitochondrial origin of the damage. Mitochondria represent th

• Since TgGC resisted several knockout attempts with

  2022-08-04

  

  Since TgGC resisted several knockout attempts with CRISPR-Cas9, we utilized traditional epitope tagging and an auxin-inducible degron (AID) system (Brown et al., 2017, Brown et al., 2018, Long et al., 2017) to detect and regulate TgGC expression. TgGC localizes to the apical cap region of the plasma

• The activation of AKT and ERK

  2022-08-04

  

  The activation of AKT and ERK1/2 results in the stabilization and increase in the co-transcriptional function of β-catenin [31], [32], [33]. Here, (R,R′)-MNF was found to reduce the levels of phospho-active AKT and ERK, which, in turn, may regulate the abundance and signaling potential of β-catenin.

• br FXR Agonists Azepinol b

  2022-08-04

  

  FXR Agonists Azepinol[4,5-b]indole 1 (hEC50=600nM, efficacy (eff)=100%) was identified as a FXR agonist lead from a high-throughput screening effort. Structure–activity relationship (SAR) studies around the azepine ring demonstrated that dialkyl substitution at C-1 led to a 30-fold improvement in

• Saxagliptin br MUTYH associated polyposis br

  2022-08-04

  

  MUTYH-associated polyposis MUTYH and its metal cofactors MUTYH harbors two vital cofactors, both of which are located remotely from the active site (Fig. 6). One of these cofactors, a [4Fe-4S]2+(Fe-S) cluster, is chelated by four Cys residues in the N-terminal domain, and positions an Fe-S clu

• The aim of this study is to explore new Glo

  2022-08-04

  

  The aim of this study is to explore new Glo-I inhibitors using the structure-based pharmacophore approach. Eighteen Glo-I co-crystallized structures have been explored to investigate their pharmacophoric features. Ninety two pharmacophoric models were generated. QSAR analysis followed by Ligand Prof

• Xie et al b reported that the combination of

  2022-08-04

  

  Xie et al. (2009b) reported that the combination of diagnostic ultrasound impulses and cyclic RGD-bearing MBs targeted for GP IIb/IIIa resulted in the successful recovery of epicardial and microvascular blood flow in swine models with acute thrombotic occlusion. It is well known that the stability o

• To assess whether this coupling mechanisms might

  2022-08-03

  

  To assess whether this coupling mechanisms might operate also in a native system of untransfected cells, we select a cell line SH-SY5Y neuroblastoma that is known to express both the dopamine transporter and the M-currents (Jiang et al., 2004; Wickenden et al., 2008). These experiments were performe

• br Experimental Procedures br Acknowledgments This work was

  2022-08-03

  

  Experimental Procedures Acknowledgments This work was supported by NIH/National Human Genome Research Institute (NHGRI) R00 HG006922 and NIH/NHGRI R01 HG008974 (to J.G.), the Huntsman Cancer Institute, and the Women’s Cancers Disease-Oriented Team at the Huntsman Cancer Institute. Research rep

• So what makes a FFAR agonist different and interesting As

  2022-08-03

  

  So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept

• br Conclusion In summary a series

  2022-08-03

  

  Conclusion In summary, a series of novel GPR40 agonists bearing phenylpropiolic rna polymerase motif with favorable metabolic stability were prepared and evaluated for their activities as GPR40 agonists. Among them, compound 9 was identified as a structurally distinct GPR40 agonist possessing po

• This study introduces a mouse

  2022-08-03

  

  This study introduces a mouse model carrying the point mutation R258W in Ffar1, which abolishes the stimulation of insulin secretion in response to long chain fatty acids. The minimal genetic alteration mirrors the human situation and has the advantage over conventional knockout/congenic mouse model

16480 records 440/1099 page Previous Next First page 上5页 436437438439440 下5页 Last page